Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
← catalyst calendarSponsored by Lexaria Bioscience Corp. (industry) · LEXX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
148actual
Sites
7
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-04 | actual | When the study began enrolling |
| Primary completion | 2025-07-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-31 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type2diabetes
Interventions
- Drug: Arm 1 - DehydraTECH-CBD alone
- Drug: Arm 2 - DehydraTECH-semaglutide alone
- Drug: Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
- Drug: Arm 4 - Rybelsus medication (semaglutide) alone
- Drug: Arm 5- Tirzepatide
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse events (TEAEs) and Serious adverse events
measured Baseline to Day 113 post first dose administration
Permalink · LEXX's whole pipeline · Catalyst calendar · Every registered study · What changed